139 related articles for article (PubMed ID: 21640588)
1. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase.
Selness SR; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Devraj RV; Messing D; Schindler JF; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4059-65. PubMed ID: 21640588
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
3. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.
Selness SR; Devraj RV; Devadas B; Walker JK; Boehm TL; Durley RC; Shieh H; Xing L; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Messing D; Yang J; Mao MK; Yalamanchili G; Vonder Embse R; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4066-71. PubMed ID: 21641211
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
5. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
[TBL] [Abstract][Full Text] [Related]
6. p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.
Natarajan SR; Wisnoski DD; Thompson JE; O'Neill EA; O'Keefe SJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4400-4. PubMed ID: 16750629
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
8. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
Natarajan SR; Doherty JB
Curr Top Med Chem; 2005; 5(10):987-1003. PubMed ID: 16178742
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-5,6-dihydro-6-substituted pyrazolo[3,4]pyridinones for neuropathic pain treatment.
Devegowda VN; Hong JR; Cho S; Lim EJ; Choo H; Keum G; Rhim H; Nam G
Bioorg Med Chem Lett; 2013 Aug; 23(16):4696-700. PubMed ID: 23820387
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
[TBL] [Abstract][Full Text] [Related]
13. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
[TBL] [Abstract][Full Text] [Related]
15. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors.
Chen MH; Fitzgerald P; Singh SB; O'Neill EA; Schwartz CD; Thompson CM; O'Keefe SJ; Zaller DM; Doherty JB
Bioorg Med Chem Lett; 2008 Mar; 18(6):2222-6. PubMed ID: 18316187
[TBL] [Abstract][Full Text] [Related]
17. p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.
Natarajan SR; Liu L; Levorse M; Thompson JE; O'Neill EA; O'Keefe SJ; Vora KA; Cvetovich R; Chung JY; Carballo-Jane E; Visco DM
Bioorg Med Chem Lett; 2006 Oct; 16(20):5468-71. PubMed ID: 16945534
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate.
Xing L; Devadas B; Devraj RV; Selness SR; Shieh H; Walker JK; Mao M; Messing D; Samas B; Yang JZ; Anderson GD; Webb EG; Monahan JB
ChemMedChem; 2012 Feb; 7(2):273-80. PubMed ID: 22174080
[TBL] [Abstract][Full Text] [Related]
19. Improved potency of pyridin-2(1H)one derivatives for the treatment of mechanical allodynia.
Visseq A; Descheemaeker A; Hérault K; Giraud F; Abrunhosa-Thomas I; Artola A; Anizon F; Dallel R; Moreau P
Eur J Med Chem; 2021 Dec; 225():113748. PubMed ID: 34392191
[TBL] [Abstract][Full Text] [Related]
20. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
